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Summary
Mutations in the MECP2 gene cause Rett syndrome
(RTT). Bdnf is a MeCP2 target gene; however, its role
in RTT pathogenesis is unknown. We examined Bdnf
conditional mutant mice for RTT-relevant pathologies
and observed that loss of BDNF caused smaller brain
size, smaller CA2 neurons, smaller glomerulus size,
and a characteristic hindlimb-clasping phenotype.
BDNF protein level was reduced in Mecp2 mutant
mice, and deletion of Bdnf in Mecp2 mutants caused
an earlier onset of RTT-like symptoms. To assess
whether this interaction was functional and potentially
therapeutically relevant, we increased BDNF expres-
sion in the Mecp2 mutant brain with a conditional
Bdnf transgene. BDNF overexpression extended the
lifespan, rescued a locomotor defect, and reversed an
electrophysiological deficit observed in Mecp2 mu-
tants. Our results provide in vivo evidence for a func-
tional interactionbetweenMecp2andBdnfanddemon-
strate the physiological significance of altered BDNF
expression/signaling in RTT disease progression.
Introduction
Rett syndrome (RTT), first described by Andreas Rett in
1966, is a neurological disorder that predominantly af-
fects girls (Hagberg, 1985; Hagberg and Hagberg,
1997). The disease occurs in children of all races and
has an estimated prevalence of 1 in 10,000–15,000 girls.
The first sign of illness is the deceleration of head growth
that begins between 2 and 4 months of age. Patients
show rapid developmental regression between the
ages of 1 to 3 years. Predominant features include social
withdrawal, loss of previously acquired skills, including
purposeful hand use and expressive language, and gait
ataxia. At this stage, many patients also develop stereo-
typic movement of the hands and autonomic dysfunc-
tions such as respiratory distress. With extensive care,
patients may survive into adulthood, yet they are
severely mentally retarded.
Mutations in the X-linked MECP2 gene (methyl-CpG
binding protein 2) account for close to 80% of RTT cases
(Amir et al., 1999; Van den Veyver and Zoghbi, 2000; Wan
*Correspondence: jaenisch@wi.mit.eduet al., 1999; Xiang et al., 2000). To study the RTT disease
mechanism, we and others established mouse models
by engineering Mecp2 gene deletions (Chen et al.,
2001; Guy et al., 2001; Shahbazian et al., 2002). Mutant
males develop normally until 5 weeks of age, when the
first manifestations resembling RTT-like symptoms are
observed, including reduced brain weight, decreased
CA2 neuron size, hindlimb clasping, and impaired loco-
motor function (Chen et al., 2001; Guy et al., 2001).
MeCP2 was initially identified as a protein that specif-
ically binds to methylated DNA in vitro and represses
transcription from methylated promoters both in vitro
and in vivo (Lewis et al., 1992; Nan et al., 1997). MeCP2
associates with a core repressor complex containing
the transcriptional repressor mSin3A and histone deace-
tylases (Jones et al., 1998), suggesting that MeCP2 may
function as a molecular linker between DNA methylation,
chromatin remodeling, and subsequent gene silencing
(Bird and Wolffe, 1999). Yet, relatively few expression
changes have been identified in Mecp2 mutants that
might explain the underlying molecular basis for RTT dis-
ease progression (Chen et al., 2003; Horike et al., 2005;
Nuber et al., 2005; Tudor et al., 2002). And the functional
consequences of these expression changes have not
been studied in vivo. In addition, MeCP2 was recently im-
plicated in regulating RNA splicing (Young et al., 2005).
One MeCP2 target is a neuronal activity-dependent
gene, Bdnf, which encodes a neurotrophic factor essen-
tial for neuronal survival (Bonni et al., 1999), differentia-
tion (Ghosh et al., 1994), and synaptic plasticity (Poo,
2001). In cultured neonatal cortical neurons, basal Bdnf
transcription is repressed by MeCP2 in the absence of
neuronal activity, but activity-dependent upregulation
of Bdnf is unaffected by Mecp2 deletion (Chen et al.,
2003). Based on these results, one would predict that,
when all the neurons are silent, the Mecp2 mutant brain
should express more BDNF than the wild-type brain
does at the basal level; yet when all the neurons are ac-
tive, the Mecp2 mutant brain should express the same
amount of BDNF as the wild-type brain does at the highly
induced level. However, these predictions are made un-
der the assumption that the level of neuronal activity is
the same in both the wild-type and Mecp2 mutant brain.
We recently reported reduced cortical activity in the
Mecp2 mutant brain (Dani et al., 2005), which may lead
to lack of activation of Bdnf upregulation in the Mecp2
mutant brain. Indeed, we show here that BDNF protein
level in the whole-brain lysate in Mecp2 mutant mice is
decreased to about 70% of the wild-type level. We also
observed similar phenotypes between the conditional
Bdnfmutant mice and theMecp2mutant mice, suggest-
ing that the moderate decrease in BDNF protein level
may mediate some defects in the Mecp2 mutant mice.
To further investigate the in vivo role of BDNF in RTT,
we manipulated BDNF expression in the postnatal brains
of Mecp2-deficient mice. We discovered that deleting
Bdnf from the Mecp2 mutant brain resulted in an earlier
onset/accelerated disease progression, whereas over-
expressing BDNF in the Mecp2 mutant brain led to later
onset/slower disease progression. Our findings provide
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342Figure 1. Lower Level of BDNF Protein in Mecp2 Mutant Brain and Phenotypic Similarities between Bdnf and Mecp2 Deficiencies
(A–C) An ELISA assay was used to quantify the amount of total BDNF protein in either the whole brain or subregions of the brain fromMecp2mutant
mice (Mecp2KO) and wild-type littermates (WT). N indicates the number of samples assayed in each genotype. Wild-type level was set at 100%.
Mecp2KO level was normalized against WT. All p values are from Student’s t tests. (A) At 2 weeks of age, no difference in BDNF protein level was
detectable between the Mecp2KO and the WT brains (103% versus 100%, p = 0.81). (B) At 6–8 weeks of age, Mecp2KO brains have less BDNF
protein than the WT brains (69% versus 100%, p = 0.01). (C) At 6–8 weeks of age, Mecp2KO mice express less BDNF protein in the cortex (79%
versus 100%, p = 0.005), the cerebellum (59% versus 100%, p = 0.009), and the rest of the brain (45% versus 100%, p = 0.01). (D) Brains from nine
wild-type (WT), five Mecp2 mutant (Mecp2KO), and ten Bdnf conditional knockout (BdnfKO) mice were freshly isolated and weighed. Student’s t
test was performed. The p values were: Mecp2KO versus WT, p = 0.0028; BdnfKO versus WT, p = 1.3E-07; and BdnfKO versus Mecp2KO, p = 0.22.
(E) Representative pictures of the hippocampal CA2 region of each indicated genotype. Neuronal cell bodies were stained with Hematoxlin (pur-
ple). The sections were counterstained with Eosin (pink). Scale bar = 50 mm. (F) At least 150 clearly stained neurons (i.e., most of the ones shown in
[E]) from three mice in each genotype were measured, using the OpenLab software. The area occupied by each neuronal soma was measured by
arbitrary units. Cell size of each genotype was normalized against the wild-type. A Student’s t test was performed to compare Mecp2KO with WT
(p = 7.6E-14), BdnfKO with WT (p = 1.4E-10), and BdnfKO with Mecp2KO (p = 0.81). Data are presented as mean6 SEM in all the bar graphs in this
figure.in vivo evidence of a functional interaction between
Mecp2 and Bdnf. Furthermore, our results indicate that
manipulating the BDNF level or the BDNF signaling
pathways may present therapeutic opportunities for
RTT patients.
Results
Mecp2 Mutant Mice Express Decreased Levels
of BDNF Protein
We used an ELISA assay to measure the level of BDNF
protein in whole-brain protein extracts prepared from
wild-type and Mecp2 mutants. At the presymptomatic
stage (2 weeks of age), no difference was detectable be-
tween mutant and wild-type mice (Figure 1A). However,
at an age when mice become symptomatic (6–8 weeks
of age), we found that the BDNF protein level in Mecp2
mutant brains was 69% of the wild-type level (p = 0.01,
Figure 1B). To find out whether BDNF protein level is de-creased throughout the brain or in specific subregions of
the brain, we separated the brain into cortex, cerebellum,
and the rest of the brain and again performed the ELISA
assay. Because BDNF protein levels were decreased in
mice displaying the typical mutant phenotype but not
in mice at the presymptomatic stage, we examined brain
subregions of symptomatic animals. At 7–8 weeks of
age, we detected reduced levels of BDNF in all three sub-
divisions of the brain (Figure 1C, 79% of the wild-type in
the Mecp2KO cortex, p = 0.005; 59% of the wild-type in
the Mecp2KO cerebellum, p = 0.009; and 45% of the
wild-type in the rest of the Mecp2KO brain, p = 0.01, re-
spectively).
Phenotypic Similarities between the Conditional
Bdnf Knockout Mice and the Mecp2 Mutant Mice
To assess whether the decreased BDNF protein level
may be involved in the neurological defects seen in
Mecp2 mutant mice, we investigated whether Bdnf and
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343Mecp2 mutant mice display phenotypic similarities. Be-
cause germline Bdnf knockout mice die shortly after
birth (Ernfors et al., 1994), we examined conditional
Bdnf knockout mice that were generated previously by
cre-mediated (cre93 transgene) deletion of a floxed
Bdnf allele in postmitotic neurons throughout the fore-
brain, part of the midbrain, and hindbrain structures
(Fan et al., 2001; Rios et al., 2001). Although Bdnf and
Mecp2 mutants display significant phenotypic differ-
ences, we detected some anatomical and functional
similarities between the respective mutants. As found
in Mecp2 mutant mice, the average brain weight of
Bdnf mutant mice was smaller than in wild-type animals
(Figure 1D). A smaller brain weight is one of the patholog-
Figure 2. Bdnf Deletion in the Mecp2 Mutant Brain Resulted in an
Earlier Onset of RTT
(A) Survival curve of each specified genotype was generated by plot-
ting the percentage of live mice (y axis) in that genotype against the
postnatal days (x axis). N is the total number of mice included in
each genotype. The black line is the survival curve of the Mecp2 mu-
tant (Mecp2KO) mice. The dashed line is the survival curve of the
Mecp2+/y;cre93;Bdnf2lox/2lox (BdnfKO) mice. The medium gray line
is the survival curve of the Mecp22/y;cre93;Bdnf2lox/+ (BDNFhet;
Mecp2KO) mice. The light gray line is the survival curve of the
Mecp22/y;cre93;Bdnf2lox/2lox (DKO) mice. A log rank test (Harrington
and Fleming, 1982) was performed to assess the statistical signifi-
cance in the difference among the survival curves: BDNFhet;
Mecp2KO versus Mecp2KO mice (p = 0.0096), DKO versus
BDNFhet;Mecp2KO (p = 0.00031), and DKO versus Mecp2KO (p =
1.3E-07). Because the wild-type mice (WT) did not die during the
time window studied here, their survival curve was not plotted in
the graph. (B) A running-wheel assay was performed to assess the
Bdnf deletion on the locomotor function of the Mecp2 mutant mice
at 4 weeks of age. Total wheel-running activity of the wild-type was
set as 100%. The activity value in other genotypes was normalized
against the wild-type value to calculate the relative activity. N above
each bar indicates the number of mice included for that genotype. All
p values were from Student’s t tests: Mecp2KO versus WT (p = 0.18),
BdnfKO versus WT (p = 0.77), DKO versus WT (p = 0.0002). Data are
presented as mean 6 SEM in all the bar graphs in this figure.ical characteristics of RTT patients(Hagberg and Hag-
berg, 1997). Furthermore, the size of CA2 neurons, as
well as the size of olfactory glomeruli (a specialized syn-
apse in the olfactory bulb), was reduced in both theBdnf
and the Mecp2 mutant mice as compared to their re-
spective wild-type littermates (Figures 1E and 1F and
Figure S1 in the Supplemental Data available with this
article online). Both the decrease of neuronal size
(Chen et al., 2001) and of the olfactory glomeruli size
have been previously described in Mecp2 mutants
(Matarazzo et al., 2004). Finally, we observed a hindlimb-
clasping phenotype in Bdnf mutant mice (Figure S2),
which has been reported in Mecp2 mutants (Guy et al.,
2001; Shahbazian et al., 2002) and is thought to mimic
the stereotypic hand-wringing behavior in RTT patients.
The phenotypic similarities between conditional Bdnf
and Mecp2 mutants are consistent with the possibility
that BDNF may mediate part of the late RTT pathologies
(such as the small brain/neuron/synapse defects). Al-
though our data suggest that BDNF and MeCP2 may
regulate similar processes in the brain, they do not distin-
guish whether the two genes function through parallel
or linear pathways. Based on these observations, we
hypothesized that changes in BDNF expression level
may modulate disease progression in Mecp2 mutant
mice. We therefore tested whether deletion or overex-
pression of BDNF in the Mecp2 mutant brain would
exacerbate or alleviate, respectively, the RTT-like symp-
toms.
Deletion of Bdnf from the Postnatal Mecp2 Mutant
Brain Results in an Earlier Onset of RTT
To study how Bdnf deletion may affect disease progres-
sion in the Mecp2 mutant mice, we crossed male
Mecp2+/y;cre93;Bdnf2lox/+ mice with female Mecp2+/2;
Bdnf2lox/+ mice to generate Mecp2-/y;cre93;Bdnf2lox/2lox
mice (DKO). When aged, the DKO mice showed a signifi-
cantly shorter lifespan (light gray line, Figure 2A) than the
Mecp2 single-mutant mice (Mecp2KO) (black line,
Figure 2A). Survival of the Mecp2 mutants was affected
by Bdnf dosage, because Mecp22/y;cre93;Bdnf2lox/+
mice (BdnfHet;Mecp2KO, medium gray line) had a
shorter lifespan than the Mecp2KO mice but survived
longer than the DKO mice (Figure 2A). Because both
the cre93;Bdnf2lox/2lox (BdnfKO, dashed line, Figure 2A)
and the cre93;Bdnf2lox/+ (BdnfHet) mice have normal life-
spans (Rios et al., 2001), the effect of BDNF level on the
survival of Mecp2KO mice may reflect a functional inter-
action of the two genes.
Mecp2 mutant mice become lethargic and display de-
creased locomotor activity beginning at 6 weeks of age
(Chen et al., 2001). To test whether Bdnf deletion in the
brain ofMecp2mutants may exacerbate locomotor dys-
function, we performed a dark-cycle locomotor activity
assay (running-wheel assay). As shown in Figure 2B,
the DKO mice showed a dramatically reduced level of
running-wheel activity at 4 weeks of age, while neither
the Mecp2 single mutants nor the Bdnf single mutants
performed significantly differently from the wild-type
mice at this age (Figure 2B). Thus, postnatal Bdnf dele-
tion in the brain of Mecp2 mutants resulted in an earlier
onset of locomotor dysfunction and earlier lethality
than was seen in Mecp2 single mutants.
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344Figure 3. BDNF Overexpression in the
Mecp2 Mutant Brain Delayed the Onset of
RTT
(A) Schematic representation of the condi-
tional BDNF-overexpression allele at the col-
lagen 1a1 locus before and after cre-medi-
ated removal of the STOP cassette. (B)
Representative pictures of the piriform cortex
and the hippocampus stained with a BDNF-
specific antibody. Note the signals in the pyr-
amidal neurons in the piriform cortex and
throughout the hippocampus were much
stronger in the BDNF-overexpression mice
(CAGGsBDNF, left) than the controls (WT,
right). (C) A quantitative PCR assay was per-
formed to assess the level of BDNF RNA in
the cortex of BDNF-overexpression mice
(CAGGsBDNF) as compared to the wild-type
control. Three mice from each genotype
were examined at each time point. (D) An
ELISA assay was performed to assess the
level of BDNF protein in the cortex of BDNF-
overexpression mice (CAGGsBDNF) as com-
pared to the wild-type control. Three mice
from each genotype were examined at each
time point. (E) Survival curve of each specified
genotype was generated by plotting the per-
centage of live mice (y axis) in that genotype
against the postnatal days (x axis). N is the
total number of mice included in each geno-
type. The red line is the survival curve of
the Mecp2 mutant (Mecp2KO) mice. The
blue line is the survival curve of the Mecp2
mutant mice that also overexpress BDNF
(CAGGsBDNF;Mecp2KO). A log rank test
was performed to assess the statistical signif-
icance in the difference between the survival
curves of the CAGGsBDNF;Mecp2KO mice
and the Mecp2KO mice (p = 0.003). Because
the wild-type mice (WT) did not die during
the time window studied here, their survival
curve was not plotted in the graph. (F) A
running-wheel assay was performed to as-
sess the BDNF overexpression on the loco-
motor function of the Mecp2 mutant mice at 6 weeks of age. Total wheel-running activity of the wild-type was set as 100%. The activity value
in other genotypes was normalized against the wild-type value to calculate the relative activity. N above each bar indicates the number of
mice included for that genotype. All p values were from Student’s t tests: Mecp2KO versus WT (p = 3E-07), CAGGsBDNF;Mecp2KO versus WT
(p = 0.71), and CAGGsBDNF;Mecp2KO versus Mecp2KO (p = 9E-05). (G) Brain weight was used as a crude measure to assess the effect of
BDNF overexpression on the size ofMecp2mutant brain. The value bars represent the average brain weight of each indicated genotype. The error
bars represent SEM. N above each bar indicates the number of mice included for that genotype. All p values were from Student’s t tests. The
average brain weight from the CAGGsBDNF;Mecp2KO mice was modestly higher than that from the Mecp2KO mice (0.350 g versus 0.329 g,
p = 0.026). However, the size of the CAGGsBDNF;Mecp2KO brain was still significantly smaller than their wild-type littermates (0.350 g versus
0.401 g, p = 3.2E-06). Data are presented as mean 6 SEM in all the bar graphs in this figure.Generation of a Conditional
BDNF-Overexpressing Allele
We next tested whether BDNF overexpression may de-
lay the onset or alleviate the RTT-like symptoms in
Mecp2 mutant mice. We engineered a conditional Bdnf
overexpression transgene using the human BDNF cDNA
(BDNFstop) under regulation by the synthetic CAGGS
promoter/enhancer/intron followed by a loxP-STOP-
loxP cassette. The transgene was targeted downstream
of the collagen 1a1 locus by frt/Flpase-mediated site-
specific integration (Beard et al., 2005; Hochedlinger
et al., 2005) in V6.5 ES cells, which were injected into
blastocysts to create the conditional BDNFstop mice. In
the presence of cre recombinase, the STOP cassette is
removed, resulting in activation of the BDNF transgene
(Figure 3A). We crossed the BDNFstop mice with the
cre93 mice to generate the BDNFstop;cre93 mice(CAGGs-BDNF), and we examined Bdnf RNA and pro-
tein levels at different ages. When compared to control
mice, Bdnf RNA levels were increased between 1.7- and
2.4-fold at 2, 5, and 10 weeks of age (Figure 3C). Sim-
ilarly, ELISA detected correspondingly increased levels
of BDNF protein (Figure 3D). To investigate the spatial
pattern of BDNF transgene expression, we performed
immunohistochemistry on brain sections using a BDNF-
specific antibody. When compared with control sec-
tions, ectopic BDNF-transgene expression was readily
detectable in the pyramidal neurons in the cortex and
hippocampus of the CAGGs-BDNF mice (Figure 3B),
as well as in other brain structures where the cre trans-
gene was expressed (data not shown), reflecting the ac-
tivity of the cre93 transgene (Fan et al., 2001). Our results
showed that cre93-mediated activation of the BDNFstop
transgene resulted in an w2-fold increase of BDNF
BDNF Modulates RTT Progression in Mouse
345Figure 4. Effects of BDNF Deletion and Over-
expression on Cortical Physiology of the
Mecp2 Mutant Mice
Whole-cell patch-clamp recordings were per-
formed to assess the effect of Bdnf deletion
and overexpression on spontaneous cortical
activity in the Mecp2 mutant mice. Spontane-
ous action potential spikes were recorded
from layer 5 pyramidal neurons of the so-
matosensory cortex from each of the indi-
cated genotypes at postnatal day 30. (Top)
Representative traces from each indicated
genotype. (Bottom) Quantification of all the
recorded neurons. N above each bar indi-
cates the number of neurons included for that genotype. All p values were from Student’s t tests. p values in (A): Mecp2KO versus WT (p =
0.038), BdnfKO versus WT (p = 0.20), DKO versus WT (p = 0.019), and DKO versus Mecp2KO (p = 0.38). p values in (B): Mecp2KO versus WT
(p = 0.004), CAGGsBDNF;Mecp2KO versus WT (p = 0.52), and CAGGsBDNF;Mecp2KO versus MT (p = 0.015). Data are presented as mean 6
SEM in all the bar graphs in this figure.expression. No obvious pathological defects were ob-
served in the CAGGs-BDNF mice (data not shown).
Overexpressing BDNF in the Mecp2 Mutant
Brain Delayed the Onset of RTT
To test whether ectopic BDNF overexpression in Mecp2
mutants influenced RTT-like symptoms, we crossed
BDNFstop males with Mecp2+/2;cre93 females to gener-
ate Mecp22/y;cre93;BDNFstop mice (CAGGsBDNF;
Mecp2KO). In contrast to the reduced lifespan of DKO
mice (compare Figure 2A), overexpression of BDNF re-
sulted in a significantly increased lifespan (Figure 3E).
Consistent with improved viability of the CAGGsBDNF;
Mecp2KO mice, we observed functional improvement
in the running-wheel assay described above. At 6 weeks
of age, when theMecp2mutant mice already show obvi-
ous symptoms, such as hindlimb clasping and reduced
locomotor activity (Figure 3F), overexpression of BDNF
resulted in a significant gain in locomotor function
(Figure 3F).
One of the defects that are commonly observed in both
human RTT patients and Mecp2 mutant mice is reduced
brain size (Chen et al., 2001; Hagberg, 1985; Hagberg and
Hagberg, 1997) (Figure 1D). Although the functional con-
sequence of such a size reduction remains unclear, our
results indicate that both BDNF and MeCP2 can affect
the brain/neuron size. Therefore, we were interested to
know whether BDNF overexpression in the Mecp2 mu-
tant brain wouldpartially rescue this defect.We observed
a modest increase in brain weight in the CAGGsBDNF;
Mecp2KO mice, compared to the Mecp2KO mice (Fig-
ure 3G, 0.35 g versus 0.329 g, p = 0.026).
Together, the common phenotypes seen in Bdnf and
Mecp2 mutants (Figures 1D–1F and Figures S1 and S2),
the accelerated development of symptoms in mice with
combined Mecp2 and Bdnf deficiency (Figure 2), and
the partial rescue of symptoms in Mecp2 mutant mice
that overexpress BDNF (Figure 3) demonstrate a func-
tional interaction between these two genes.
Effects of BDNF Deletion and Overexpression on
Cortical Physiology of the Mecp2 Mutant Mice
To define the mechanistic basis to the interaction be-
tweenBdnf andMecp2, we tested whetherBdnfdeletion
or BDNF overexpression affected electrophysiological
properties in Mecp2 mutant neurons. We performed
whole-cell current-clamp recordings in layer 5 pyramidalneurons of the somatosensory cortex in mice of the re-
spective genotypes based on our recent demonstration
that acute slice preparations from Mecp2 mutant mice
displayed a reduced spontaneous activity as compared
to the wild-type littermate controls (Dani et al., 2005).
This defect was detectable in animals as young as 2
weeks of age and was most prominent in 5-week-old mu-
tant mice. We investigated whether the deletion of Bdnf
inMecp2mutant neurons would further reduce the spon-
taneous firing rate. At postnatal day 30, consistent with
our previous result, we found that the firing rate of layer
5 pyramidal neurons of the somatosensory cortex from
the Mecp2KO slices was reduced as compared to wt
controls (0.85 Hz versus 3.72 Hz, p = 0.0038, Figure 4A),
while the firing rate in the BdnfKO slices was indistin-
guishable from the wt controls (4.62 Hz versus 3.72 Hz,
p = 0.20). The averge firing rate of the DKO neurons
was slightly lower than that of the Mecp2KO neurons
(0.43 Hz versus 0.85 Hz, Figure 4A), though this was not
statistically significant (p = 0.44). In contrast, we found
a significantly increased firing rate in pyramidal neurons
from Mecp2 mutant mice that expressed ectopic BDNF
when compared to the Mecp2 single mutants (2.84 Hz
versus 0.94 Hz, p = 0.015, Figure 4B). These results dem-
onstrate that electrophysiological activity in Mecp2 mu-
tant neurons correlates with BDNF levels, which in turn
are associated with locomotor function and viability, fur-
ther substantiating the functional interaction between
Bdnf and Mecp2.
Discussion
In neurons, BDNF expression is tightly regulated by neu-
ronal activity. At increased activity levels, the mecha-
nism of activity-dependent Bdnf transcription involves
calcium influx through voltage-gated calcium channel
(Ghosh et al., 1994), activation of Cam kinase IV (Shieh
and Ghosh, 1999), and phosphorylation of CREB (Tao
et al., 1998). Previously, we reported no difference in
Bdnf RNA level (w100-fold of basal level) between
Mecp2-deficient and wild-type neurons treated with
KCl, which suggests that MeCP2 is not directly involved
in the upregulation of Bdnf by increased activity (Chen
et al., 2003). Yet, when treated with tetrodotoxin (TTX),
which blocks activity, a 2-fold increase of the Bdnf
RNA level was detected inMecp2-deficient as compared
to wild-type neurons. This suggests that MeCP2 may
Neuron
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tivity-suppressed neurons (Chen et al., 2003). Our pres-
ent results found a lower level of BDNF protein in mutant
brains, an observation which is in apparent conflict with
the previous results (Chen et al., 2003). To resolve this
conflict, it is important to emphasize the differences in
the previous and the present experimental design. Our
previous experiments were performed in vitro and com-
pared Bdnf RNA levels in homogeneous WT and
Mecp2KO neuronal cultures where neuronal activity
was artificially kept at an increased or suppressed level
through KCl or TTX treatment, respectively. In contrast,
the present study compared BDNF protein levels in wt
(normal neuronal activity) and Mecp2KO (reduced neu-
ronal activity) brains that are at different activity states.
Given that BDNF expression depends on neuronal activ-
ity, we favor the hypothesis that Mecp2 deficiency re-
duces neuronal activity, thereby indirectly causing a de-
creased BDNF protein level. Consistent with this
possibility, we found progressively reduced neuronal
activity in layer 5 pyramidal neurons in the somatosen-
sory cortex of Mecp2 mutant mice (Dani et al., 2005).
This chronic reduced activity in a major class of BDNF-
producing neurons in the Mecp2 mutant brain is detect-
able at 2 weeks and may subsequently result in less ac-
tivation of BDNF expression than the wild-type level.
While our results demonstrate that the level of BDNF pro-
tein decreased in the Mecp2 mutants, the molecular
mechanism is not clear. Previous results, based upon
neural cultures, have demonstrated that the basal tran-
scription rate of Bdnf promoter III is regulated by
MeCP2. It will be interesting to investigate whether the
other Bdnf promoters are also affected in the Mecp2
mutant brains.
BDNF is a well-known neurotrophic factor. The de-
creased level of BDNF protein in theMecp2mutant brain
may contribute to the small brain/neuron/synapse
defect, a typical atrophic response caused by Bdnf defi-
ciency. The phenotypic similarities between the Mecp2
deficiency and the Bdnf deficiency are consistent with
such a possibility. More importantly, the opposing
effects of Bdnf deletion and overexpression on the sur-
vival, locomotor function, and cortical physiology of the
Mecp2 mutant mice are consistent with a functional in-
teraction between BDNF and MeCP2 in RTT pathogene-
sis. Although our data do not distinguish whether MeCP2
and BDNF signal through parallel or linear pathways,
they suggest that BDNF and MeCP2 may regulate the
same biological process. It will be important to define
what downstream targets of BDNF overlap with the
affected targets in the Mecp2 mutant mice.
Several aspects of the Mecp2mutant phenotype were
ameliorated by postnatal ectopic expression of BDNF.
For example, BDNF overexpression markedly improved
the locomotor function of the Mecp2 mutant mice in the
dark-cycle running-wheel assay. It is possible that the
improved motor function allows mutant mice more effi-
cient access to food and water, which may, at least in
part, explain the significant extension of lifespan.
Furthermore, BDNF overexpression rescued an electro-
physiological deficit in the Mecp2 mutant cortex, result-
ing in an increased spontaneous firing of layer 5 pyrami-
dal neurons. This result is consistent with many previous
reports that studied the effect of BDNF on synaptictransmission (Schuman, 1999). It is possible that the
overexpression of BDNF in Mecp2 mutant brains also
increased neuronal activity in other parts of the brain,
such as the motor cortex, which contributed to the
enhanced locomotor function.
Abnormal BDNF expression has been linked to many
human diseases, such as Huntington’s disease (Canals
et al., 2004), schizophrenia, and depression (Angelucci
et al., 2005). Our finding links Bdnf and Mecp2 in vivo
and suggests that RTT may be another human disease
that is partially mediated through BDNF. Moreover, over-
expression of such a pleotrophic factor in the brain has
been shown to ameliorate symptoms in a mouse model
of Huntington’s disease (Cepeda et al., 2004; Kells
et al., 2004). Similarly, our results suggest therapeutic
opportunities through manipulation of BDNF expres-
sion. Although Bdnf is only one of many genes regulated
by MeCP2, it is the first one shown to modulate disease
progression of Mecp2 mutant mice. Future studies will
be aimed at understanding the molecular basis that
underlies its effect on the course of RTT disease.
Experimental Procedures
Mice Mating and Genotyping
Many of the mouse alleles used in this study have been reported pre-
viously. These include the conditional Bdnf knockout allele (Rios
et al., 2001), the cre93 transgene (Fan et al., 2001), and the Mecp2
germline mutant allele (Chen et al., 2001). Genotyping of these alleles
was performed as described in these papers. A PCR assay was de-
veloped to genotype the conditional BDNF overexpression allele.
The primers are 50-CCCTCCATGTGTGACCAAGG-30 (col/frt-B); 50-
GCACAGCATTGCGGACATGC-30 (col/frtA1); and 50-GCAGAAGCG
CGGCCGTCTGG-30 (col/frtC1). A 551 bp band indicates a BDNFstop
flip-in allele. A 300 bp band indicates a wild-type allele. Male
Bdnf2lox/+ mice were mated with femaleBdnf2lox/+;cre93 mice to gen-
erateBdnf2lox/2lox;cre93 mice (conditionalBdnf knockout mice). Male
Mecp2+/y;cre93;Bdnf2lox/+ mice were mated with female Mecp2+/2;
Bdnf2lox/+ mice to generate Mecp22/y;cre93;Bdnf2lox/2lox mice
(DKO). Male BDNFstop mice were mated with female cre93 mice to
generate BDNFstop;cre93 mice (CAGGsBDNF mice). Male BDNFstop
mice were mated with female Mecp2+/2;cre93 mice to generate
Mecp22/y;cre93;BDNFstop mice (CAGGsBDNF;Mecp2KO).
Generation of Conditional BDNF-Overexpressing Mice
An MluI/NotI fragment containing human BDNF cDNA with an HA tag
was cut out from pAdCIG (a gift from Dr. Rita Balice-Gordon), blunt-
ended, and ligated with an EcoRI cut/blunt-ended pCAGGSTurbo-
cre vector to generate pCAGGS-BDNF-HA. A SpeI/SfiI fragment con-
taining the CAGGS promoter, the BDNF cDNA, the HA tag, and an
RBGpolyA signal was cut out from the pCAGGS-BDNF-HA and
subcloned into the EcoRV site of pPGK-ATG-FRT (no EcoRI) vector.
A loxP-STOP-loxP cassette was cloned immediately upstream of the
BDNF cDNA to generate the conditional BDNF-overexpressing con-
struct. The procedure to flip-in the conditional BDNF-overexpressing
construct into the modified collagen 1a1 locus in ES cells was done
as previously described (Hochedlinger et al., 2005). Hygromycin-
resistant ES clones were analyzed by Southern blot. Correctly
targeted ES clones were expanded and frozen. For diploid blastocyst
injections, fertilized zygotes were isolated from the oviducts of day
0.5 pregnant B6D2F1 females and allowed to develop to the blasto-
cyst stage in culture. About ten ES cells were injected per blastocyst.
Injected blastocysts were transferred into day 2.5 pseudopregnant
or Swiss recipient females. Chimeric mice were bred with C57B6
mice to screen for germline transmission by coat color.
BDNF ELISA
A BDNF ELISA kit (Promega) was used to measure BDNF protein
expression as per the manufacturer’s instructions. All solutions
were from the kit or made exactly as instructed by the manufacturer.
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subregions of the brain in certain experiments) and lysed. Total pro-
tein concentration was measured by using a Dc Protein Assay kit
from BIO-RAD. An acid treatment of the brain lysate was adopted
to increase the amount of free BDNF. In each assay, duplicate wells
were assigned for each sample. A VERSAmax microplate reader was
used to measure signal intensity from the wells. A standard curve
was generated from the BDNF standard wells on each plate, using
the SPF3.1.2 software. The total amount of BDNF per well was calcu-
lated based on the standard curve. The relative BDNF value was then
calculated by normalizing the amount of BDNF against the total pro-
tein input.
Brain Weight, Immunohistochemistry,
and CA2 Neuron Measurement
For brain weight analysis, brains were freshly isolated and weighed.
For CA2 neuron measurement, brains were perfused with 4% para-
formaldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 4%
paraformaldehyde overnight at 4ºC, washed in PBS, processed by
a TISSUE-TEK VIP machine (Miles Scientific), and imbedded in par-
affin. Five-micron serial coronal sections were taken through the
whole brain. Digital pictures were taken for the CA2 region of the hip-
pocampus. The soma area (arbitrary unit) of projection neuron was
determined by tracing the outline of the neuronal cell body cut
through the level of the nucleolus, using OpenLab software. For im-
munohistochemistry, brains were perfused with 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 4% paraformal-
dehyde overnight at 4ºC, cryoprotected in 20% sucrose, imbedded in
OCT, and frozen on dry ice. Fifty-micron serial coronal sections were
taken through the whole brain. Floating sections were stained with
a rabbit polyclonal BDNF-specific antibody (Chemicon), followed
by a biotinylated goat anti-rabbit secondary antibody, and visualized
with an immuno-peroxidase stain (Vector).
Quantitative PCR
Total RNA was isolated by using the Absolutely RNATM RT-PCR Mini-
prep kit (Stratagene). One microgram of RNA from each sample was
used to generate cDNA, by using the SuperScriptTM First-Strand
Synthesis System for RT-PCR kit (Invitrogen). Two microliter of the
total RT product was used for each PCR reaction. CyberGreen dye
(Molecular Probes) and HotStar Taq (Qiagen) were included in the
PCR mix. Two sets of primers for Bdnf and one set of primers for
GAPDH were used. Bdnf set 1: 50-AGAGCTGTTGGATGAGGACC
AG-30 (forward), 50-CAAAGGCACTTGACTACTGAGCA-30 (reverse).
Bdnf set 2: 50-TACGAGACCAAGTGCAATCCC-30 (forward), 50-CGCA
CGTACGACTGGGTAGTT-30 (reverse). GAPDH set: 50-AATGGGAAG
CTTGTCATCAACG-30 (forward), 50-GAAGACACCAGTAGACTCCAC
GACATA-30 (reverse). Triplicate reactions were run for each sample
for both BDNF and GAPDH. Reactions were run on the ABI PRISM
7000 Sequence Detection System (Applied Biosystems). Threshold
cycle for each reaction was determined, using the ABI Prism 7000
SDS software (Applied Biosystems). Bdnf values were first normal-
ized against the GAPDH values for each sample. Normalized wild-
type values were set as 100% to calculate relative values.
Dark-Cycle Running-Wheel Activity Assay
Total dark-cycle running-wheel activities were recorded in a wheel
running cage connected to a Mini-counter (Opto-Varimax-Mini-A,
Columbus Instruments). For each measurement, a mouse was
placed at least 3 hr before the starting time into a standard laboratory
mouse cage with fresh bedding. Recording started at the time when
the lights were normally turned off (19:00 Eastern Standard Time) and
stopped at 8:00 the next morning, 1 hr after the lights normally came
back on. Wild-type activity was set as 100% to calculate relative
activity in the other genotypes.
Electrophysiology
The standard artificial cerebrospinal fluid (ACSF) contained (in mM)
NaCl, 126; KCl, 3; MgSO4, 2; NaHPO4, 1; NaHCO3, 25; CaCl2, 7;
H2O, 2; and Dextrose, 14. For spontaneous firing, the ACSF was mod-
ified as follows: KCl, 3.5; MgCl2, 0.5; CaCl2, 1. Osmolality was ad-
justed to 318 6 2 mOsm. Whole-cell pipette solution contained
(in mM) KCl, 20; K-Gluconate, 100; HEPES, 10; Biocytin 0.1% (w/v);
Mg-ATP, 4; Na-GTP, 0.3, and Na-Phosphocreatinine, 10. Three-hundred mm thick coronal sections containing the somatosensory
cortex were cut in cold ACSF using a Leica VT1000S slicer. Slices
were incubated in standard ACSF at 37ºC for 15–20 min immediately
after slicing and subsequently at room temperature. Slices were pre-
incubated (w45 min) and perfused in modified ACSF as previously
described (Maffei et al., 2004). Somatic whole-cell recordings were
obtained from visually identified layer 5 (L5) pyramidal cells as previ-
ously described (Dani et al., 2005). Glass pipette electrodes (4–6 MU
resistance) were pulled from borosilicate capillaries (World Precision
Instruments, Inc, Sarasota, FL) using a Sutter P92 Flame/Brown
Puller (Sutter Instruments Co, Novato, CA). All data acquisition and
analysis were performed using Igor Pro (Wavemetrics, Lake Oswego,
OR) software and in-house programs. Data were acquired using
a Multiclamp 700A (Axon Instruments/Molecular Devices, Union
City, CA) computer-controlled amplifier at 10 KHz and low-pass fil-
tered at 3 KHz. In all experiments, slices were fixed and stained for
biocytin to confirm the identity of the recorded cells.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/49/3/341/DC1/.
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